Last reviewed · How we verify

NCT06987825: China-AF

Chinese Atrial Fibrillation Registry

Recruiting now Last updated 23 May 2025
What this trial tests

trial in Atrial Fibrillation (AF) in 100,000 participants. Currently enrolling.

Timeline
1 August 2011
Primary endpoint
31 December 2035
31 December 2035

Quick facts

Lead sponsorBeijing Anzhen Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100,000
Start date1 August 2011
Primary completion31 December 2035
Estimated completion31 December 2035
Sites2 locations across China

Conditions studied

Sponsor

Beijing Anzhen Hospital

Who can join

18 and older, any sex, with Atrial Fibrillation (AF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, observational cohort study aims to establish a long-term registry of adult patients with atrial fibrillation (AF) in China to comprehensively characterize patient profiles and evaluate real-world management and outcomes over time. The objectives of the study are to: * Describe the demographic, clinical, and treatment characteristics of AF patients across different stages of disease progression. * Assess the effectiveness and safety of various AF treatment strategies, including oral anticoagulation, catheter ablation, and left atrial appendage closure, in routine clinical practice. * Identify patient- and treatment-related factors that influence therapeutic outcomes. * Explore the role of advanced technologies and artificial intelligence in improving procedural performance, risk stratification, and clinical decision-making in AF care. Participants will undergo standardized baseline evaluation and longitudinal follow-up to collect data on heart rhythm monitoring, treatment exposures, healthcare utilization, clinical events, and patient-reported outcomes. This cohort will generate real-world evidence to inform personalized and evidence-based management of AF.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Association of left ventricular geometry with outcomes and treatment response in atrial fibrillation and heart failure with preserved ejection fraction.
    Ren L, Peng X, Li M, He L, et al · · 2026 · PMID 42158122 · DOI 10.3389/fmed.2026.1824509
  2. Association between anemia and 1-year recurrence of paroxysmal atrial fibrillation after radiofrequency ablation.
    Li E, Cao Z, Li D, Zhao Z, et al · · 2025 · PMID 41169521 · DOI 10.1515/jtim-2025-0042

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation (AF)

Currently open trials in the same condition.

Other Beijing Anzhen Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06987825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing